Details for Patent: 8,895,617
✉ Email this page to a colleague
Which drugs does patent 8,895,617 protect, and when does it expire?
Patent 8,895,617 protects GOCOVRI and OSMOLEX ER and is included in two NDAs.
This patent has four patent family members in three countries.
Summary for Patent: 8,895,617
Title: | Composition and method for treating neurological disease |
Abstract: | Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. |
Inventor(s): | Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Jasper, GA), Porter; Seth (San Carlos, CA), Meyerson; Laurence R. (Las Vegas, NV), Burkoth; Timothy S. (Lake Bluff, IL) |
Assignee: | Adamas Pharmaceuticals, Inc. (Emeryville, CA) |
Application Number: | 14/451,273 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,895,617 |
Patent Claim Types: see list of patent claims | Use; Composition; Device; |
Patent landscape, scope, and claims: | More… ↓ |
Drugs Protected by US Patent 8,895,617
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Supernus Pharms | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS | ⤷ Subscribe | |||
Supernus Pharms | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS | ⤷ Subscribe | ||||
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF PARKINSON'S DISEASE | ⤷ Subscribe | ||||
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS IN ADULT PATIENTS WITH PARKINSON'S DISEASE | ⤷ Subscribe | ||||
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-004 | Apr 22, 2020 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF PARKINSON'S DISEASE | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,895,617
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 2588296 | ⤷ Subscribe | |||
European Patent Office | 1845968 | ⤷ Subscribe | |||
European Patent Office | 2623099 | ⤷ Subscribe | |||
World Intellectual Property Organization (WIPO) | 2006058236 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |